New diagnostic tool for Hypoactive Sexual Desire Disorder (HSDD) in women
- Details
- Category: Boehringer Ingelheim
Results from a study published today in the Journal of Sexual Medicine show that a new, easy to use five-question diagnostic tool can significantly reduce the time it takes to diagnose the most common form of female sexual dysfunction (FSD), generalised, acquired Hypoactive Sexual Desire Disorder* (HSDD).
Pfizer Expands Portfolio of Generic Medicines in the U.S. and Europe
- Details
- Category: Pfizer
Pfizer Inc (NYSE: PFE) announced today that it has entered into a series of agreements with Aurobindo Pharma Ltd., a pharmaceutical company based in India, to commercialize medicines that are no longer patent protected, and have lost market exclusivity in the United States and Europe, further progressing its Established Products Business Unit strategy.
AstraZeneca and MAP Pharmaceuticals, Inc. Announce Worldwide Collaboration
- Details
- Category: AstraZeneca
AstraZeneca and MAP Pharmaceuticals, Inc. have announced an exclusive worldwide agreement to develop and commercialise Unit Dose Budesonide (UDB), MAP Pharmaceuticals' proprietary nebulised formulation of budesonide. UDB is being developed by MAP Pharmaceuticals as a potential treatment for paediatric asthma and is currently in Phase III clinical development.
Advances in Renal Cancer Journalists' Award
- Details
- Category: Bayer
Bayer HealthCare and the Association of German Medical Journalists (VDMJ) have jointly announced the 2009 Advances in Renal Cancer Journalistsâ Award Europe, which will honor journalists who have dealt with the issue of renal cancer in a critical and objective manner. The award, endowed with EUR 7,500, is donated by Bayer HealthCare. Eligible for the award are printed media, radio, television and film reports.
Novartis shareholders approved 25% dividend increase
- Details
- Category: Novartis
Novartis shareholders have followed the Board of Directors' recommendations for all proposed resolutions at the Group's Annual General Meeting. These included a 25% increase in the dividend payment for 2008, the rejection of the introduction of a consultative vote on the remuneration report and the election of William Brody, M.D., Ph.D. as a new Board member.
Abbott Successfully Completes Tender Offer for Shares of Advanced Medical Optics
- Details
- Category: Abbott
Abbott today announced the successful completion of the tender offer by its wholly owned subsidiary Rainforest Acquisition Inc. to purchase all of the outstanding shares of common stock of Advanced Medical Optics (AMO). The tender offer expired at midnight Eastern time on Tuesday, Feb. 24, 2009, and was not extended.
Pfizer Discontinues Development of Two Phase 3 Compounds
- Details
- Category: Pfizer
Pfizer Inc has announced that, following a review of the development and commercial portfolios in the Primary Care Business Unit, it is terminating Phase 3 development programs for the investigational compounds esreboxetine for fibromyalgia and PD 332,334 for generalized anxiety disorder (GAD).
More Pharma News ...
- Nycomed reports a satisfactory 2008
- Schering-Plough announces collaboration with World Health Organization
- Encouraging results support further development of Almirall's long-acting beta-agonist (LABA)
- Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics
- The safety of patients is of utmost importance to Merck
- GSK initiates phase III programme for novel type 2 diabetes medication, Syncria® (albiglutide)
- FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab